Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

ClinicalTrials.gov ID: NCT06060977

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06060977. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 1:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants With 50% or Greater Scalp Hair Loss

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.

Study identification

NCT ID
NCT06060977
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Inmagene LLC
Industry
Enrollment
29 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 25, 2023 (Actual)
Primary completion
Jan 14, 2025 (Actual)
Completion
Jan 14, 2025 (Actual)
Last update posted
Feb 9, 2026

2023 – 2025

United States locations

U.S. sites
11
U.S. states
10
U.S. cities
11
Facility City State ZIP Site status
Northwest Arkansas Clinical Trials Center, PLLC/ Hull Dermatology P.A. Rogers Arkansas 72758 —
Torrance Clinical Research Institute Inc. Lomita California 90717 —
Alliance Clinical Research of Tampa Tampa Florida 33615 —
Dawes Fretzin Clinical Resarch Group, LLC Indianapolis Indiana 47906 —
Options Research Group West Lafayette Indiana 47906 —
Lahey Hospital & Medical Center Burlington Massachusetts 01803 —
Great Lakes Research Group Inc. Bay City Michigan 48706 —
Skin Cancer and Dermatology Institute Reno Nevada 89509 —
Skin Search of Rochester, Inc. Rochester New York 14623 —
Stride Clinical Research LLC Sugar Land Texas 77479 —
Dermatology Specialists of Spokane Spokane Washington 99202 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06060977, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 9, 2026 · Synced Nov 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.